ICON Public Limited (NASDAQ:ICLR) Shares Sold by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC lessened its holdings in ICON Public Limited (NASDAQ:ICLR - Free Report) by 8.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,572 shares of the medical research company's stock after selling 5,943 shares during the quarter. Motley Fool Wealth Management LLC owned about 0.08% of ICON Public worth $17,978,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ICLR. Ashton Thomas Private Wealth LLC acquired a new position in ICON Public in the 2nd quarter worth approximately $54,000. ORG Partners LLC acquired a new stake in shares of ICON Public during the 2nd quarter worth approximately $59,000. GAMMA Investing LLC grew its stake in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company's stock worth $82,000 after purchasing an additional 87 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company's stock worth $95,000 after purchasing an additional 42 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company's stock worth $130,000 after purchasing an additional 226 shares during the period. Institutional investors and hedge funds own 95.61% of the company's stock.

ICON Public Price Performance

ICLR stock traded up $3.30 during midday trading on Wednesday, reaching $216.29. The stock had a trading volume of 658,765 shares, compared to its average volume of 741,035. The company's fifty day simple moving average is $246.01 and its 200 day simple moving average is $292.48. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company has a market cap of $17.84 billion, a price-to-earnings ratio of 23.74, a price-to-earnings-growth ratio of 1.58 and a beta of 1.21. ICON Public Limited has a 52-week low of $183.38 and a 52-week high of $347.72.

ICON Public (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company had revenue of $2.03 billion for the quarter, compared to analysts' expectations of $2.13 billion. During the same quarter in the prior year, the firm earned $3.10 EPS. The firm's revenue was down 1.2% on a year-over-year basis. As a group, sell-side analysts predict that ICON Public Limited will post 13.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ICLR shares. Barclays dropped their price objective on shares of ICON Public from $330.00 to $275.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Baird R W cut shares of ICON Public from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 24th. Leerink Partners reiterated an "outperform" rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Evercore ISI decreased their target price on ICON Public from $360.00 to $350.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Finally, StockNews.com lowered ICON Public from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ICON Public presently has a consensus rating of "Moderate Buy" and a consensus price target of $292.45.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.